+91 8617752708

Journal of Advances in Biology & Biotechnology, 2394-1081,Vol.: 16, Issue.: 3

Review Article

Treat Oculocutaneous Albinism with Gene Therapy

 

Martin L. Nelwan1*

1Department of Animal Science – Other, Nelwan Institution for Human Resource Development Jl. A. Yani No. 24, Palu, Indonesia.

Article Information

Editor(s):

(1) Andrzej Kowalski, Department of Biochemistry and Genetics, Institute of Biology, Jan Kochanowski University, Kielce, Poland.

Reviewers:

(1) Adam Reich, University of Rzeszow, Poland.

(2) Asaad Ahmed Ghanem, Mansoura University, Egypt.

(3) Silvana Guerriero, University of Bari, Italy.

Complete Peer review History: http://www.sciencedomain.org/review-history/22563

Abstracts

Oculocutaneous albinism (OCA) is a group of hereditary recessive disorder recognized as a loss of pigmentation. OCA can derive from mutations in different genes that produce melanin. These mutations cause disturbances to get a standard melanin synthesis. There are 7 types of oculocutaneous albinism. These include OCA1, OCA2, OCA3, OCA4, OCA5, OCA6, and OCA7. To help OCA patients, it may include management of such as hats with brims and sunscreens. An effective therapy is unavailable for albinism at present. However, to fight OCA in the future, gene therapy can be used. Gene therapy can include use of such as retrovirus vectors, adenovirus vectors, and CRISPR/Cas9 system. Research results in animal models have shown remarkable advances. It means that the gene therapy will be helpful to treat people with albinism.

Keywords :

Albinism; albino; oculocutaneous albinism; gene therapy.

Full Article - PDF    Page 1-12

DOI : 10.9734/JABB/2017/38504

Review History    Comments

Our Contacts

Guest House Road, Street no - 1/6,
Hooghly, West Bengal,
India

+91 8617752708

 

Third Floor, 207 Regent Street
London, W1B 3HH,
UK

+44 20-3031-1429